Cognition Therapeutics closes $2.

Lemere continued.. Cognition Therapeutics closes $2.5 million Series A1 financing Cognition Therapeutics Inc., a drug discovery firm developing novel, little molecule disease-modifying treatments for Alzheimer’s, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Medication candidate status. The round was led by Golden Seeds, among the nation’s largest angel investing groupings, and was syndicated with Tech Coastline Angels.D., J.D.The serotonin transporter regulates the known degree of serotonin, a human brain transmitter that plays a part in spiritual experience, among many other behavioral traits. The vasopressin receptor has been shown in lots of animal studies to modulate social communication and affiliative bonding behaviors. Both are elements involved in the age-old human interpersonal expression of dance. The genetic proof was corroborated by two questionnaires distributed by the experts to the dancers. One is the Tellegen Absorption Scale , that correlates aspects of spirituality and altered states of awareness, and the other may be the Tridimensional Character Questionnaire , a way of measuring the necessity for social get in touch with and openness to communication.

Related Articles

Other Articles from "hypertension":